Our paper on the novel role of a psychiatric disease-related circRNA on synaptic gene expression and cognition was just published as an immediate communication in Molecular Psychiatry. #circRtrain https://t.co/qz5cOso9z4
Introducing Circular Genomics' MindLight™, the first circular RNA-based assay designed to predict whether a patient with #depression will respond to #SSRI antidepressant treatment.
#MindLight#MajorDepressiveDisorder#CircRNA
Learn more: https://t.co/86xY9W0Jnr
Circular Genomics announces findings from exclusive access EMBARC study, showing promising results that circular RNA can serve as a robust and reliable blood biomarker for predicting depression remission and response to SSRI treatment.
https://t.co/UWVtsh0fbB
#mentalhealth#SSRI
Interested in fellowship training in #addiction medicine? Possibly developing circuit biomarkers and #neuromodulation therapies? Consider applying to this K12 fellowship program at @MGHPsychiatry :
https://t.co/0kiMBqYlK4
Hiring a postdoc: want to work at the interface of patient-derived cellular models and genomics? We model neurodevelopmental disorders and try to apply those models for therapeutic development. Job here: https://t.co/7ygtLWdTp3 + smiling lab people here: https://t.co/bfdJZwo2An
Exciting results from our clinical study findings at Circular Genomics on the use of circRNAs as robust biomarkers of response to antidepressant treatment. https://t.co/poUXC5NuLL
A new study by MIT scientists shows that mice with Alzheimer’s exposed to 40 Hz vibration for an hour a day for several weeks showed improved brain health and motor function compared to untreated controls. @MIT_Picower @DrLiHueiTsai
Read more: https://t.co/x0pkyhDwQp
Our work identifying proteomics signatures of COVID infection, that were then used to create prediction models for COVID-related death is now published on @iScience_CP
https://t.co/F0MSfdjWIk
@WUSTLmed
Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. By Bruce J. Kirenga et al. @Makerere#fluvoxamine#SSRI#covid19#psychiatry#OpenAccess https://t.co/s86JtVsoSl
Today's FDA approval of #Trofinetide could bring new, much needed hope to many with #Rettsyndrome and their families. In 2009 @SurLabMIT made the first preclinical showing that IGF-1 could have therapeutic potential. https://t.co/BbPstqBZEp @mit@mitscience@mitbrainandcog
AIM eSymposium Workshops 2022-2023 | Autophagy, Inflammation and Metabolism Center of Biomedical Research Excellence - full program in place, check it out! https://t.co/Lqz1EV5xH7
i think we really found something very exciting- biggest congratz to hero Cledi and the many others w contributions: miR-7 controls glutamatergic transmission and neuronal connectivity in a Cdr1as-dependent manner #circRNA@cledi_cj@zolotarg https://t.co/yxkNLcSyfk